• Explore /
  • Poster
  • / Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1–high locally advanced non-small cell lung cancer.

Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1–high locally advanced non-small cell lung cancer.

Abstract Poster

Authors

null

Steven H. Lin

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Steven H. Lin , Stephanie L. Pugh , Anne S. Tsao , Martin Joseph Edelman , Anthony Doemer , Charles B. Simone II, Saumil Gandhi , Sai Bikkina , Nagla Fawzy Abdel Karim , Xinglei Shen , Shahed N Badiyan , Kristin Ann Higgins , Arnab Chakravarti , Maria Werner-Wasik , John M Schellenkamp , Rebecca Paulus , Jeffrey D. Bradley

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03801902

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8513)

DOI

10.1200/JCO.2022.40.16_suppl.8513

Abstract #

8513

Poster Bd #

140

Abstract Disclosures

Similar Posters

First Author: Hossein Borghaei

First Author: Siddharth Sheth

First Author: Benjamin Besse

First Author: Mustafa Özgüroğlu